Gå offline med appen Player FM !
HOT TOPICS - ANNEXA-I Trial
Manage episode 424352436 series 1459666
Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion had not been well studied, until the ANNEXA-I Trial. To discuss this week's Hot Topic, Nicholas Morris, MD is joined by one of the trial's collaborators, Ashkan Shoamanesh, MD as well as clincial pharmacist Andrew Webb, PharmD, BCCCP.
Listeners can also join the NCS Journal Club which will be discussing the ANNEXA-I Trial on "X" / Twitter on Tuesday, July 16th starting at 9am CT.
102 episoder
Manage episode 424352436 series 1459666
Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion had not been well studied, until the ANNEXA-I Trial. To discuss this week's Hot Topic, Nicholas Morris, MD is joined by one of the trial's collaborators, Ashkan Shoamanesh, MD as well as clincial pharmacist Andrew Webb, PharmD, BCCCP.
Listeners can also join the NCS Journal Club which will be discussing the ANNEXA-I Trial on "X" / Twitter on Tuesday, July 16th starting at 9am CT.
102 episoder
Tüm bölümler
×Välkommen till Player FM
Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den är den bästa podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.